Childhood Obesity Risk Markers (MARIOBE)

Condition(s) studied

Investigational drug(s) / intervention(s)

early transcriptomic markers: during a scheduled surgery before the age of 4 years, collection of a blood sample (2.5 mL in a PAXgene tube) and two adipose tissue fragments, each measuring 5 mm x 5 mm x 5 mm. tracking of weight and height curves from birth to age 6

Study summary

Metabolic diseases, including childhood obesity, represent a major public health challenge. Studies in mice have identified transcriptomic markers in adipose tissue capable of predicting a predisposition to obesity prior to any weight gain. The MARIOBE project aims to translate this approach to young children (≤ 4 years old) in order to identify individual vulnerability to obesity at an early stage.

Eligibility

Primary outcome measure(s)

• transcriptomic markers in children under 4 years of age that predict a predisposition to being overweight at age 6 (BMI > IOTF25). — perioperative
  Ranking of the discriminative capacity of adipocyte and blood transcripts before 4 years of age to predict the development of overweight (BMI \> IOTF25) at age 6, using Partial Least Squares Discriminant Analysis (PLS-DA).

Trial sites (1)

More University Hospital, Clermont-Ferrand trials in France

Other trials for the same condition